Phase II Study of Ramucirumab Plus Irinotecan Combination Therapy as Second-Line Treatment in Patients with Advanced Gastric Cancer : HGCSG1603

Yasuyuki, Kawamoto; Satoshi, Yuki; Kentaro, Sawada; Tsuji, Yasushi; Dazai, Masayoshi; Okuda, Hiroyuki; Meguro, Takashi; Harada, Kazuaki; Sekiguchi, Mari; Okada, Kazufumi; Ito, Yoichi M.; Sakata, Yuh; Sakamoto, Naoya; Komatsu, Yoshito

Phase II Study of Ramucirumab Plus Irinotecan Combination Therapy as Second-Line Treatment in Patients with Advanced Gastric Cancer : HGCSG1603

Yasuyuki, Kawamoto; Satoshi, Yuki; Kentaro, Sawada et al.

The Oncologist, 2022, 27(8), e642-e649

Permalink : https://hdl.handle.net/2115/86546

このアイテムのアクセス数:412件（2026-01-15 04:14 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数	説明
https://doi.org/10.1093/oncolo/oyac086

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	metadata only access
URI	https://hdl.handle.net/2115/86546
タイトル	Phase II Study of Ramucirumab Plus Irinotecan Combination Therapy as Second-Line Treatment in Patients with Advanced Gastric Cancer : HGCSG1603
著者	Yasuyuki, Kawamoto ; Satoshi, Yuki ; Kentaro, Sawada ; Tsuji, Yasushi ; Dazai, Masayoshi ; Okuda, Hiroyuki ; Meguro, Takashi ; Harada, Kazuaki ; Sekiguchi, Mari ; Okada, Kazufumi ; Ito, Yoichi M. ; Sakata, Yuh ; Sakamoto, Naoya ; Komatsu, Yoshito
e-Rad_Researcher 60755601 著者名 Yasuyuki, Kawamoto
著者名 Satoshi, Yuki
著者名 Kentaro, Sawada
著者名 Tsuji, Yasushi
著者名 Dazai, Masayoshi
著者名 Okuda, Hiroyuki
著者名 Meguro, Takashi
著者名 Harada, Kazuaki
著者名 Sekiguchi, Mari
著者名 Okada, Kazufumi
著者名 Ito, Yoichi M.
著者名 Sakata, Yuh
e-Rad_Researcher 10334418 著者名 Sakamoto, Naoya
e-Rad_Researcher 60333598 著者名 Komatsu, Yoshito
言語	英語
キーワード	gastric cancer
	ramucirumab
	irinotecan
	second-line treatment
発行日	2022-08
出版者	Oxford University Press
収録物名	The Oncologist
巻(号)	27(8)
ページ	e642-e649
抄録	This article reports the results of a trial that assessed the efficacy and safety of ramucirumab plus irinotecan combination therapy as second-line treatment in patients with previously treated advanced gastric cancer. Background Ramucirumab is a human IgG1 monoclonal vascular endothelial growth factor receptor-2 antibody that inhibits tumor cell growth and affects the tumor cell microenvironment. We assessed the efficacy and safety of ramucirumab plus irinotecan combination therapy as second-line treatment in patients with previously treated advanced gastric cancer. Materials and Methods Patients with advanced gastric cancer refractory or intolerant to primary chemotherapy were included. Ramucirumab 8 mg/kg plus irinotecan 150 mg/m(2) combination therapy was administered every 2 weeks. The primary endpoint was progression-free survival rate at 6 months and secondary endpoints were overall survival, progression-free survival, response rate, safety, and dose intensity for each drug. Results Thirty-five patients were enrolled between January 2018 and September 2019. The progression-free survival rate at 6 months was 26.5% [95%CI, 13.2%-41.8%, P = .1353)]. Median progression-free and overall survivals were 4.2 months (95%CI, 2.5-5.4 months) and 9.6 months (95%CI, 6.4-16.6 months), respectively. The overall response rate was 25.9% (95%CI, 11.1-36.3%) and disease control rate was 85.2% (95%CI, 66.3-95.8%). Grade >= 3 adverse events that occurred in >10% of patients included neutropenia, leucopenia, anemia, anorexia, and febrile neutropenia. No death or new safety signals with a causal relation to the study treatment were observed. Conclusion Although the primary endpoint was not achieved statistically, combination therapy of ramucirumab plus irinotecan showed anticancer activity and a manageable safety profile for second-line treatment of patients with advanced gastric cancer.
資源タイプ	学術雑誌論文
出版タイプ	Version of Record
PISSN	1083-7159
関連情報	PMID 35579511
関連情報 (isIdenticalTo)	出版社版DOI https://doi.org/10.1093/oncolo/oyac086